CASE Op-Ed – Morning Consult: COVID-19 Provides a Roadmap for Effective Health Care Policy
Matthew Kandrach – President, CASE April 16, 2012 In a milestone revelation this month, it was announced that the United...
HUGE Mistake: White House MFN Drug Policy Will Devastate Innovation into New Treatments and Cures
November 20, 2020 As a leading advocate for consumers and patients across the country, CASE strongly condemns today’s new...
CASE Statement Opposing President’s Order Embracing Pricing Index & Foreign Importation of Medications
Gerard Scimeca – Chairman, CASE July 24, 2020 As a strong voice for American patients and consumers, CASE urges...
More Socialized Medicine: CASE Opposes Dangerous Anti-Consumer Healthcare Proposal
June 29, 2020 As an advocate for consumers across the country, CASE urges House lawmakers to vote against H.R. 1425,...
Rep. Dan Crenshaw Breaks Down Why H.R.3 is a Dangerous Idea
“I don’t think people would be supportive of this idea if they realized there would be so many fewer cures.”...
.@POTUS’ IRA is driving up Part D premiums for millions of Medicare beneficiaries, yet Dems like @SenSanders continue to help tout this disastrous legislation. The Biden-Harris @WhiteHouse is misleading the public on their policy’s real impact.
Two weeks from election day, the supposedly independent @FCC is proposing price regulation of #broadband by restricting what data plans companies can offer.
By prohibiting usage-based plans, the FCC would end up increasing prices FOR EVERYONE, including low-data users!
CASE Letter Urges FDA & FTC to Scrutinize Deal Between L’Oréal and Galderma -- "Both companies are currently under investigation or facing sizable lawsuits from claims that they have used harmful chemicals in their products."
https://caseforconsumers.org/2024/10/21/case-letter-urges-fda-ftc-to-scrutinize-deal-between-loreal-and-galderma/